Navigation Links
Lupin Gets USFDA Approval for Meloxicam

Lupin Ltd today said it has got the approval of US Food and Drug Administration (US FDA) for its Abbreviated New Drug Application (ANDA) for Meloxicam tablets used in the treatment of osteoarthritis and rheumatoid arthritis. //

The approval is for Meloxicam tablets of strengths of 7.5 mg and 15 mg , the company informed the Bombay Stock Exchange.

"The approval of our Meloxicam ANDA further reinforces Lupin's ability on submitting high quality dossiers and gaining approval in time. Our thorough execution has enabled us to launch the product immediately," Lupin Managing Director Kamal K Sharma said.

Meloxicam is a generic equivalent of Boehringer Ingelheim's non-steroidal anti-inflammatory drug (NSAID), Mobic. Its sales in the US were approximately 1.1 billion dollars for the 12-month period ended December 2005 according to IMS Health, it added.

This is the company's 14th ANDA approval from US FDA, it said.

Source:PTI News
'"/>




Page: 1

Related medicine news :

1. Lupin flour may cause peanut allergy like reactions
2. Lupin Gets USFDA Approval For Quinapril Tablets
3. US Court Rules Against Lupin in Ramipril Patent Case
4. Lupin Gets DCGI Nod For Phase II Clinical Trials On Desoside-P
5. Lupin Gets Tentative Nod from FDA for Antidepressant Drug
6. Morepan to file new drug applications with the USFDA
7. Ranbaxy Gets USFDA Approval For Doxycycline Tablets
8. Cadila Gets Tentative USFDA Nod For Pravastatin Sodium Tablets
9. Lupin Gets USFDA Approval For Quinapril Tablets
10. Ranbaxy Gets USFDA Nod For Simvastatin
11. Aurobindo Receives Approval from USFDA for anti-AIDS drug
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Lupin Gets USFDA Approval for Meloxicam

Breaking Medicine Technology:DecisionView Launches StudyOptimizer(TM) 4 2DecisionView Launches StudyOptimizer(TM) 4 3The Army Awards Follow-On Contract for Autonomous Airway Management to Energid Technologies 2Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 2Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 3Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 4Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 5Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 6Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 7Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 8Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 9Phase III Study Demonstrates INVEGA(R) SUSTENNA(TM) (paliperidone palmitate) Statistically Similar to RISPERDAL(R) CONSTA(R) (risperidone) Long-Acting Injection 10Sosei and Vectura Announce Start of Phase III Clinical Study With NVA237 4659 1Sosei and Vectura Announce Start of Phase III Clinical Study With NVA237 4659 2Sosei and Vectura Announce Start of Phase III Clinical Study With NVA237 4659 3Sosei and Vectura Announce Start of Phase III Clinical Study With NVA237 4659 4Natural born divers and the molecular traces of evolution 9035 1Natural born divers and the molecular traces of evolution 9035 2Reading the brain without poking it 9033 1Reading the brain without poking it 9033 2Reading the brain without poking it 9033 3Reading the brain without poking it 9033 4Reading the brain without poking it 9033 5